TLR4 and colitis: This dual inhibition of TLR4 and RAGE, both of which contribute to NFκB activation, underscores the mechanistic superiority of the ALG-RSV-CSNPs formulation in controlling inflammation at multiple levels, leading to improved therapeutic outcomes in DSS-induced colitis.